# NAUTILUS CE-mark Trial of the FLOWer Cerebral Embolic Protection Device

Study · id `cardio:ct-nct04704258` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04704258](<https://clinicaltrials.gov/study/NCT04704258>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04704258

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT04704258. Allocation not applicable; no masking; primary purpose other. Start 2021-05-03 (actual); primary completion 2023-06-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT04704258, source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)
- Started: 2021-05-03 (actual) (ClinicalTrials.gov record NCT04704258, source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)
- Primary completion: 2023-06-06 (actual) (ClinicalTrials.gov record NCT04704258, source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)
- Completion: 2023-06-06 (actual) (ClinicalTrials.gov record NCT04704258, source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)
- Countries: Belgium; Italy (ClinicalTrials.gov record NCT04704258, source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04704258-2024-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: NAUTILUS CE-mark Trial of the FLOWer Cerebral Embolic Protection Device
- Acronym: NAUTILUS
- Condition: Aortic Valve Stenosis
- Condition: Intracranial Embolism and Thrombosis
- Intervention (Procedure): TAVI (Transcatheter Aortic Valve Implant)
- Intervention (Device): FLOWer Embolic Protection System
- Lead sponsor: AorticLab Srl
- Lead sponsor class: INDUSTRY
- Collaborator: Meditrial Europe Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 0135014eac3491296a5ac848fd427129c0014a55dd39b7dc9742edcf387b026c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
